New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CPNO;MTOR;KMP;HA;ENDP;RIMM;BBRY;CHK;BA;BIOC;AMZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
September 17, 2014
16:00 EDTAMZNOptions Update; September 17, 2014
iPath S&P 500 VIX Short-Term Futures down 24c to 27.63. Option volume leaders: AAPL TSLA BAC TWTR AMZN X WLT KO PBR according to Track Data.
12:22 EDTENDPOn The Fly: Midday Wrap
Subscribe for More Information
12:15 EDTENDPAuxilium climbs, QLT falls after Endo submits takeover bid
Shares of drug maker Auxilium (AUXL) are rallying after another company in the sector, Endo (ENDP), offered to buy Auxilium for $28.10 per share. Endo said that Auxilium's 12 FDA approved products in urology, orthopedic and other areas are "natural complements" to Endo's men's health and pain products, while Auxiium said it would consider the offer. The potential deal, however, jeopardizes Auxiium's prior agreement to acquire another drugmaker, QLT Inc. (QLTI). WHAT'S NEW: Endo announced last night that it had made a cash and stock bid of $28.10, or $2.2B, for Auxilium. The latter company announced this morning that it would "carefully review" the offer. The two companies have "significant synergy opportunities" and the deal is "expected to be immediately accretive" to Endo's EPS, the hopeful buyer added. WHAT'S NOTABLE: On June 26, Auxilium announced that it would merge with Canada's QLT Inc. According to Sterne Agee analyst Shibani Malhotra, Endo said last night that it was not interested in acquiring QLT and Auxilium would have to choose between merging with QLT and being acquired by Endo. ANALYST REACTION: Although Endo's bid represents a 30%+ premium to Auxilium's closing price yesterday, Jefferies analyst Thomas Wei believes that the synergies outlined by Endo justify a higher takeout price. Specifically, the analyst thinks that Auxilium could be acquired for $34 to $45 per share. Wei kept a $34 price target and Buy rating on Auxilium. For his part, Malhotra predicted that Auxilium would approve the Endo deal and reject the QLT merger. The bid appears to be substantially accretive for Endo, added the analyst, who kept a $75 price target and Buy rating on Endo's shares. PRICE ACTION: In early afternoon trading, Auxilium surged over 43% to $30.88 and Endo advanced 6.5% to $69.35, while QLT dropped 12% to $5.46.
10:56 EDTBABoeing Airplanes head mulls making 52 737s monthly, Reuters says
Boeing Commercial Airplanes CEO Ray Connor said that the company is aiming to produce close to 52 737 aircrafts per month beginning in 2018, according to Reuters, citing comments from Connor. Connor said, "Now, I can tell you that the demand is there for those airplanes, significant demand. So I'm not uncomfortable with the timing or with rate." Reference Link
09:11 EDTENDPEndo offer likely to be accepted by Auxilium, says Sterne Agee
Subscribe for More Information
09:10 EDTENDPOn The Fly: Pre-market Movers
Subscribe for More Information
08:44 EDTENDPBioDelivery Sciences remains takeout candidate for Endo, says Summer Street
Summer Street believes a potential takeover of BioDelivery Sciences (BDSI) by partner Endo (ENDP) is no less likely after Endo made a bid to acquire Auxilium (AUXL). The firm believes an Endo buyout of BioDelivery is likely a 2015 event when BioDelivery's Bunavail for opioid dependence is on the market and BEMA Buprenorphine is facing FDA approval. Summer Street says it is a buyer of BioDelivery Sciences on weakness this morning and keeps a Buy rating on the name with a $28 price target.
08:06 EDTENDPAuxilium likely to require higher bid from Endo, says MKM Partners
After Endo (ENDP) made a $28.10 per share bid for Auxilium (AUXL), MKM Partners believes that Endo will probably have to bid at least $32 to buy Auxilium. The firm raised its price target on Auxilium to $32 from $26 and reiterates a Buy rating.
07:58 EDTENDPEndo, Auxilium deal can create significant synergies, says Canaccord
Subscribe for More Information
07:46 EDTBABoeing and Avalon finalize order for 787 Dreamliners, 737 MAXs
Subscribe for More Information
07:39 EDTENDPEndo deal for Auxilium highly complimentary, says UBS
Subscribe for More Information
07:15 EDTENDPEndo bid for Auxilium positive, says Wells Fargo
Subscribe for More Information
07:14 EDTENDPAuxilium to 'carefully review' proposal from Endo for $28.10 per share
Subscribe for More Information
07:12 EDTENDPQLT Inc. provides update on merger with Auxilium
QLT Inc. (QLTI) announces that it has been advised by Auxilium Pharmaceuticals (AUXL) that Auxilium has received an unsolicited offer from Endo International (ENDP) to acquire all of the issued and outstanding shares of Auxilium. Auxilium has further advised QLT that the board of Auxilium is reviewing the Endo Proposal, and has not withdrawn, modified, withheld, changed or qualified its recommendation with respect to the proposed merger with QLT pursuant to the Agreement and Plan of Merger among QLT, Auxilium, QLT Holding, and QLT Acquisition, dated June 25. The Merger Agreement continues in full force and effect. In accordance with the Merger Agreement, QLT has consented to the adoption by Auxilium of a stockholder rights plan in response to the Endo Proposal.
07:11 EDTENDPAnalysts say Auxilium QLT deal could be snarled by Endo bid, Reuters says
Subscribe for More Information
07:04 EDTENDPAuxilium could be worth $34-$45/share in takeout, says Jefferies
Jefferies believes Auxilium (AUXL) could be worth more than the $28.10 per share offer by Endo (ENDP). The firm says it can get to valuations of $34-$45 per share for Auxilium under a takeout scenario. Jefferies thinks proposed acquisition cost "leaves considerable value on the table." It keeps a Buy rating on Auxilium with a $34 price target. In pre-open trading, Auxilium is trading well above Endo's offer price at $30.26 per share, up 41% or $8.74.
06:59 EDTAMZNAmazon.com ads could increase EPS, says Pacific Crest
Pacific Crest believes that Amazon.com's ad initiatives could boost its EPS by $2.60 and raise its operating margin by one point in 2018. The firm quotes ad tech experts with whom it spoke as saying that the company is "a potential juggernaut in the ad industry" and is "on a $1B run rate." The firm keeps a $460 price target and Outperform rating on the shares.
06:36 EDTENDPEndo volatility expected to move on Endo acquisition proposal
Subscribe for More Information
06:27 EDTBABoeing tanker to make first flight five months later than planned, WSJ reports
A Boeing aerial refueling tanker is expected to make its first flight in November, five months later than planned, reports the Wall Street journal. Major General John Thompson, the head of the KC-46A Pegasus tanker program, said he was "disappointed" about the delay in the test aircraft's first flight. Reference Link
06:25 EDTENDPAuxilium volatility expected to move on Endo acquisition proposal
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use